Braveheart Bio (BRVE) European Society of Cardiology Heart Failure Congress 2026 presentation summary

Study background and objectives

• BHB/HRS-1893 is a selective, reversible cardiac myosin inhibitor designed for rapid onset, minimal LVEF impact, and ease of use.

• CMIs have shown disease-modifying effects in obstructive HCM; this study explores their potential in non-obstructive HCM (nHCM), where treatment options are limited.

• The Phase 2, randomized, double-blind, placebo-controlled study evaluated efficacy and safety of BHB/HRS-1893 in adults with symptomatic nHCM.

Study design and patient characteristics

• 84 adults with nHCM were randomized to low-dose, high-dose, or placebo groups; all had LVEF ≥60% and NYHA class II-III.

• Key endpoints included safety (LVEF <50%), biomarkers (NT-proBNP, cTnI), KCCQ-CSS, pVO2, and echocardiographic measures.

• Baseline characteristics were balanced across groups, with mean ages 44.5–51 years and 100% NYHA class II.

Dosing and biomarker outcomes

• Most patients titrated to the highest available dose; 71% of high-dose group reached 60 mg BID.

• NT-proBNP levels dropped rapidly and durably, with a 68% reduction in the high-dose group.

• High-sensitivity cTnI levels decreased by 60% in the high-dose group, indicating reduced heart tissue injury.